Pharma BD Deal Intelligence
A small platform tuck-in that got quietly absorbed into J&J's IP estate rather than becoming a visible commercial engine — no blockbuster traceable to it, no public disaster either.
Full analysis, sources & comparables →J&J's Harlan Weisman called TransForm 'a strong, strategic addition to our pharmaceutical research, discovery and development model,' highlighting…
J&J acquires TransForm Pharmaceuticals for $230 million, reporting the cash deal for the Lexington, MA-based formulation-discovery specialist and the expected…
J&J completed the $230M cash acquisition of TransForm in April 2005, gaining a privately held formulation/crystallization platform with ~80 employees.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
J&J acquires TransForm for ~$230M cash to gain crystalline-form drug discovery platform. Closed April 2005.
A small platform tuck-in that got quietly absorbed into J&J's IP estate rather than becoming a visible commercial engine — no blockbuster traceable to it, no public disaster either.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / TransForm Pharmaceuticals, Inc. (this deal) | 2005 | $230M | 41 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2005 deals · Johnson & Johnson deals